Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Shigella Infections (Shigellosis) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Shigella Infections (Shigellosis) - Pipeline Review, H2 2014', provides an overview of the Shigella Infections (Shigellosis)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Shigella Infections (Shigellosis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Shigella Infections (Shigellosis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Shigella Infections (Shigellosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Shigella Infections (Shigellosis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Shigella Infections (Shigellosis) Overview 6 Therapeutics Development 7 Pipeline Products for Shigella Infections (Shigellosis) - Overview 7 Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis 8 Shigella Infections (Shigellosis) - Therapeutics under Development by Companies 9 Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes 10 Shigella Infections (Shigellosis) - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Shigella Infections (Shigellosis) - Products under Development by Companies 13 Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes 14 Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development 15 Anacor Pharmaceuticals, Inc. 15 GlycoVaxyn AG 16 Novartis AG 17 Shigella Infections (Shigellosis) - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 1790GAHB Vaccine - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 GVXNSD-133 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 INX-201 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 KKL-35 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 shigella vaccine - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 shigella vaccine - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 shigella vaccine 1 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 shigellosis [Shigella flexneri 2a] (whole cell) vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Shigetec - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule for Shigellosis - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecule to Inhibit Rns and VirF for Bacterial Infections - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Shigella Infections (Shigellosis) - Recent Pipeline Updates 35 Shigella Infections (Shigellosis) - Dormant Projects 36 Shigella Infections (Shigellosis) - Discontinued Products 37 Shigella Infections (Shigellosis) - Product Development Milestones 38 Featured News & Press Releases 38 Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 38 Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 38 Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions 39 Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 40 Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 41 Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella 41 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Number of Products under Development for Shigella Infections (Shigellosis), H2 2014 7 Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Shigella Infections (Shigellosis) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 15 Shigella Infections (Shigellosis) - Pipeline by GlycoVaxyn AG, H2 2014 16 Shigella Infections (Shigellosis) - Pipeline by Novartis AG, H2 2014 17 Assessment by Monotherapy Products, H2 2014 18 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Route of Administration, H2 2014 21 Number of Products by Stage and Molecule Type, H2 2014 23 Shigella Infections (Shigellosis) Therapeutics - Recent Pipeline Updates, H2 2014 35 Shigella Infections (Shigellosis) - Dormant Projects, H2 2014 36 Shigella Infections (Shigellosis) - Discontinued Products, H2 2014 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
